SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Biogen
An SI Board Since August 1996
Posts SubjectMarks Bans Symbol
1686 75 0 BIIB
Emcee:  Harold Engstrom Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
411 Rick and V1... Biogen has been an excellent company to play both puts and callAnnie-9/2/1997
410 I left PMG in '94. However, I was also a private investor, and I couldnscaram(o)uche-9/2/1997
409 <<My bet is that BGEN has a composition of matter patent on one of the laVector1-9/2/1997
408 ITP, anti-factor VIII and lupus all make sense. However, they're the targescaram(o)uche-9/2/1997
407 Vector: Nobody that I know was expecting the PNAS manuscript by Kirk et al. Ascaram(o)uche-9/2/1997
406 Rick and Harold, after Rick posted the abstacts on CD40 I went back and read aVector1-9/2/1997
405 Could someone on this thread enlighten us as to how Biogen is using the power opragat-8/31/1997
404 Rick, Thanks for the clarification... Annie-8/29/1997
403 Rick, from BGEN's 10K. It looks like they start clinicals for CD40 this yeVector1-8/29/1997
402 Annie: Layman's terms....... it is one hot sh*t project. It may be of iscaram(o)uche-8/29/1997
401 Richard, And now in layman's terms please? And to think I was going to bAnnie-8/29/1997
400 Leuk Lymphoma 1997 Feb;24(5-6):393-422 CD40/CD40 ligand interactions in normascaram(o)uche-8/27/1997
399 Blood 1994 Oct 1;84(7):2305-2314 Expression and function of CD40 on Hodgkin ascaram(o)uche-8/27/1997
398 Am J Pathol 1996 Dec;149(6):1953-1961 CD40 is a prognostic marker in primary scaram(o)uche-8/27/1997
397 Transplantation 1996 Jan 15;61(1):4-9 CD40-gp39 interactions play a critical scaram(o)uche-8/27/1997
396 Clin Immunol Immunopathol 1994 Oct;73(1):11-18 Collagen-induced arthritis as scaram(o)uche-8/27/1997
395 J Immunol 1995 Feb 1;154(3):1470-1480 Interaction between CD40 and its ligandscaram(o)uche-8/27/1997
394 Crit Rev Immunol 1996;16(1):59-108 Functions of CD40 and its ligand, gp39 (CDscaram(o)uche-8/27/1997
393 J Exp Med 1996 Mar 1;183(3):801-810 The relative contribution of the CD28 andscaram(o)uche-8/27/1997
392 Thyroid 1996 Aug;6(4):267-273 Antibody to gp39, the ligand for CD40 significascaram(o)uche-8/27/1997
391 J Clin Immunol 1997 Jan;17(1):11-20 T cells of lupus and molecular targets foscaram(o)uche-8/27/1997
390 Immunology 1997 Mar;90(3):421-426 Suppression of murine thyroiditis via blockscaram(o)uche-8/27/1997
389 Science 1996 Sep 27;273(5283):1864-1867 Requirement for CD40 ligand in costimscaram(o)uche-8/27/1997
388 Immunol Res 1997 Feb;16(1):59-70 The CD40 ligand. At the center of the immunescaram(o)uche-8/27/1997
387 I am new to biotech. Would appreciate some guide to learn about this field for QKSAND-8/26/1997
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News